Strategic Exit Sanifit has undergone multiple high-profile acquisitions and partnerships by Vifor Pharma, signaling a validated clinical-stage portfolio and favorable exit dynamics which can ease due diligence and collaboration discussions with potential buyers or co-development partners.

Cardio-Renal Focus SNF472 targets calcification in end-stage renal disease patients undergoing hemodialysis, addressing a high-need cardio-renal niche that aligns with nephrology and cardiovascular therapeutic opportunities, suggesting cross-sell potential to nephrology-focused KOLs and payers.

Phase II Readiness Post-Phase I completion and active Phase II programs in ESRD and calciphylaxis present near-term development milestones that can be leveraged to structure partnerships, co-funding, or milestone-driven deals with larger pharma players seeking late-stage entry signals.

Global Footprint With a US subsidiary and Europe-based operations, Sanifit offers a transatlantic collaboration runway for multinational vendors, contract research, and manufacturing partners seeking to expand nephrocardio portfolios across markets.

Funding Momentum Recent funding rounds and strategic interest from Vifor indicate investor confidence and potential for additional financing or collaboration grants; this can facilitate joint ventures, licensing deals, or accelerated clinical programs to de-risk partnerships.